Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Novo Nordisk A/S
Melanie Davies; Louise Færch; Ole K Jeppesen; Arash Pakseresht; Sue D Pedersen; Leigh Perreault; Julio Rosenstock; Iichiro Shimomura; Adie Viljoen; Thomas A Wadden; Ildiko Lingvay; STEP 2 Study Group